A Phase I Study of MK-5108, an Oral Aurora A Kinase Inhibitor, in Both Monotherapy and in Combination with Docetaxel in Patients with Advanced Solid Tumors.

    May 2010 in “ Journal of Clinical Oncology ”
    S. E. Minton, Patricia LoRusso, A. Craig Lockhart … Mark N. Stein
    Studysummary This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on ascopubs.org →
    Discuss this study in the Community →